In this study, treatment with Metformin was more effective than Pirfenidone or MitoQ in reducing both the levels of COL4A1 and COL1A1 as well as preventing a shift to glycolysis, typically occurring in cancer cells and pro-fibrotic myofibroblasts. Here, COL4A1 is linked to cancer.